---
schema_version: "secwatch.filing_event.v1"
accession: "0001093557-25-000111"
form_type: "8-K"
ticker: "DXCM"
cik: "0001093557"
company_name: "DEXCOM INC"
filed_at: "2025-05-01T23:59:59+00:00"
generated_at: "2026-05-22T23:42:15.795975+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# DexCom Q1 revenue $1.04B (+12% YoY); guides FY25 gross margin ~62% (down); announces $750M buyback

## Summary
- GAAP net income $105.4M ($0.27 diluted EPS) vs $146.4M ($0.36) YoY; non-GAAP EPS $0.32 flat.
- Revenue $1.036B (+12% reported, +14% organic); US +15%, intl +7% (organic +12%).
- FY25 guidance: revenue $4.6B (+14%), non-GAAP gross margin ~62% (cut from prior), op margin ~21%, EBITDA margin ~30%.
- Board authorized $750M share repurchase program through June 30, 2026.
- Post-quarter FDA clearance for G7 15-day system; expanded PBM coverage and Stelo on Amazon.

## SEC filing metadata
- accession: 0001093557-25-000111
- form_type: 8-K
- ticker: DXCM
- cik: 0001093557
- company_name: DEXCOM INC
- filed_at: 2025-05-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1093557/000109355725000111/0001093557-25-000111-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1093557/000109355725000111/dxcm-20250501.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001093557-25-000111
- JSON: https://secwatch.observer/filing/0001093557-25-000111.json
- Plain text: https://secwatch.observer/filing/0001093557-25-000111.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.